{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T17:00:54Z","timestamp":1790182854206,"version":"4.1.0"},"reference-count":43,"publisher":"BMJ","issue":"Suppl 2","license":[{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"unspecified","delay-in-days":22,"URL":"https:\/\/creativecommons.org\/licenses\/by\/3.0\/igo\/"}],"funder":[{"DOI":"10.13039\/100004423","name":"World Health Organization","doi-asserted-by":"publisher","award":["Not Applicable"],"award-info":[{"award-number":["Not Applicable"]}],"id":[{"id":"10.13039\/100004423","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Sex Reprod Health"],"accepted":{"date-parts":[[2026,8,11]]},"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To systematically review the contraceptive safety and effectiveness of ormeloxifene, a non-hormonal selective oestrogen receptor modulator, among reproductive-age women.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A comprehensive search was performed across MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials (CENTRAL) and Google Scholar. No restrictions were applied regarding language, geography or publication year. Eligible studies included interventional and observational designs that evaluated the contraceptive effectiveness and\/or safety of ormeloxifene. Two reviewers independently extracted data using a standardised form, assessed the risk of bias for individual studies, and graded the certainty of evidence using design-appropriate tools.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The review included 14 studies on contraceptive use of ormeloxifene and 41 studies assessing its safety in non-contraceptive contexts. Twelve contraceptive studies reported Pearl Indices ranging from 0.48 to 4.2 per 100 woman-years, with failure rates between 0.8% and 10.1%. No serious adverse events such as thromboembolism or hepatotoxicity were reported. Two cases of benign endometrial hyperplasia were reported, and transient reductions in lactation were noted among 5.7% of women at 1\u2009month, decreasing to 2% at 6 months among women using ormeloxifene as contraception. Infant exposure during breastfeeding remained below 10% of the maternal dose. The most common side effects were menstrual irregularities, leading to discontinuation in up to 31.5% of users. Continuation rates were high at 3\u20136 months (&gt;85\u2013100%), declining to 27\u201391% in larger cohorts involving longer follow-up extending beyond 12 months. Method satisfaction was consistently high (75\u201395%). All 14 studies on contraceptive use were conducted in India, had a high risk of bias, and only four were multicentre studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Ormeloxifene shows promise as a moderately effective, safe and user-acceptable contraceptive option. The current evidence is limited by methodological weaknesses and geographic concentration. High-quality, large-scale studies in diverse populations are essential to establish ormeloxifene\u2019s comparative effectiveness and safety with greater certainty and support its inclusion in global contraceptive guidelines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PROSPERO registration number<\/jats:title>\n                    <jats:p>CRD42024622516.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjsrh-2026-203329","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T16:05:16Z","timestamp":1790179516000},"page":"s13-s22","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Contraceptive effectiveness and safety of ormeloxifene: a systematic review"],"prefix":"10.1136","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8623-9113","authenticated-orcid":false,"given":"Tesfaye","family":"Tufa","sequence":"first","affiliation":[{"name":"Department of Obstetrics & Gynecology, School of Medicine, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Idrees","sequence":"additional","affiliation":[{"name":"Interdisciplinary School of Health Sciences, University of Ottawa, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goodness Ogeyi","family":"Odey","sequence":"additional","affiliation":[{"name":"Department of Health Policy, The London School of Economics and Political Science, London, UK"},{"name":"London School of Hygiene & Tropical Medicine, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8536-3470","authenticated-orcid":false,"given":"Asantesana","family":"Kamuyango","sequence":"additional","affiliation":[{"name":"Department of Public Health, National Cheng Kung University, Tainan, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3447-244X","authenticated-orcid":false,"given":"Nancy","family":"Kidula","sequence":"additional","affiliation":[{"name":"UNDP\/UNFPA\/UNICEF\/WHO\/World Bank Special Programme of Research, Development of Sexual and Research Training in Human Reproduction (HRP Research), Department of Sexual and Reproductive Health and Research, World Health Organization, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6225-1302","authenticated-orcid":false,"given":"Mojisola","family":"Alere","sequence":"additional","affiliation":[{"name":"Department of Community Medicine, University of Ibadan, Ibadan, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Komal Preet","family":"Allagh","sequence":"additional","affiliation":[{"name":"UNDP\/UNFPA\/UNICEF\/WHO\/World Bank Special Programme of Research, Development of Sexual and Research Training in Human Reproduction (HRP Research), Department of Sexual and Reproductive Health and Research, World Health Organization, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6595-2035","authenticated-orcid":false,"given":"Rita","family":"Kabra","sequence":"additional","affiliation":[{"name":"UNDP\/UNFPA\/UNICEF\/WHO\/World Bank Special Programme of Research, Development of Sexual and Research Training in Human Reproduction (HRP Research), Department of Sexual and Reproductive Health and Research, World Health Organization, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Thorne","sequence":"additional","affiliation":[{"name":"Department of Obstetrics & Gynecology, School of Medicine, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4180-7858","authenticated-orcid":false,"given":"James","family":"Kiarie","sequence":"additional","affiliation":[{"name":"UNDP\/UNFPA\/UNICEF\/WHO\/World Bank Special Programme of Research, Development of Sexual and Research Training in Human Reproduction (HRP Research), Department of Sexual and Reproductive Health and Research, World Health Organization, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"key":"2026092309050934000_52.Suppl_2.s13.1","doi-asserted-by":"publisher","DOI":"10.1002\/med.1011"},{"key":"2026092309050934000_52.Suppl_2.s13.2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2741\/e807","article-title":"Centchroman: a safe reversible postcoital contraceptive with curative and prophylactic activity in many disorders","volume":"10","author":"Kamboj","year":"2018","journal-title":"Front Biosci (Elite Ed)"},{"key":"2026092309050934000_52.Suppl_2.s13.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2009.11.007"},{"key":"2026092309050934000_52.Suppl_2.s13.4","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-030373","article-title":"Scoping review to map evidence on mechanism of action, pharmacokinetics, effectiveness and side effects of centchroman as a contraceptive pill","volume":"9","author":"Kabra","year":"2019","journal-title":"BMJ Open"},{"key":"2026092309050934000_52.Suppl_2.s13.5","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1002\/ijgo.70107","article-title":"Clinical outcomes among Centchroman users across six medical college hospitals in India","volume":"170","author":"Radhika","year":"2025","journal-title":"Int J Gynaecol Obstet"},{"key":"2026092309050934000_52.Suppl_2.s13.6","doi-asserted-by":"crossref","unstructured":"Agarwal K , Dewan R . Evaluation of acceptability, safety and continuation rates of centchroman as postabortion nonsteroidal contraceptive pill. Contraception 2023;121. doi:10.1016\/j.contraception.2023.109961","DOI":"10.1016\/j.contraception.2023.109961"},{"key":"2026092309050934000_52.Suppl_2.s13.7","doi-asserted-by":"crossref","first-page":"21","DOI":"10.5005\/jp-journals-10006-1116","article-title":"Ormeloxifene versus medroxyprogesterone acetate (MPA) in the treatment of dysfunctional uterine bleeding: a double-blind randomized controlled trial","volume":"3","author":"Bellad","year":"2011","journal-title":"J South Asian Fed Obstet Gynaecol"},{"key":"2026092309050934000_52.Suppl_2.s13.8","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.3390\/medicina58111503","article-title":"Evaluation of the safety and efficacy of ormeloxifene, a selective estrogen receptor modulator and medroxyprogesterone acetate in women with non-structural abnormal uterine bleeding: a randomized clinical trial","volume":"58","author":"Mir","year":"2022","journal-title":"Medicina (B Aires)"},{"key":"2026092309050934000_52.Suppl_2.s13.9","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1111\/jog.13105","article-title":"Efficacy of ormeloxifene versus oral contraceptive in the management of abnormal uterine bleeding due to uterine leiomyoma","volume":"42","author":"Kriplani","year":"2016","journal-title":"J Obstet Gynaecol Res"},{"key":"2026092309050934000_52.Suppl_2.s13.10","doi-asserted-by":"crossref","first-page":"78","DOI":"10.4103\/jms.jms_115_21","article-title":"Prospective clinical study to evaluate role of centchroman in regression of mastalgia in rural population","volume":"36","author":"Mishra","year":"2022","journal-title":"J Med Soc"},{"key":"2026092309050934000_52.Suppl_2.s13.11","first-page":"C10","article-title":"Effectiveness of centchroman on regression of fibroadenosis and mastalgia","volume":"10","author":"Rajswaroob","year":"2016","journal-title":"J Clin Diagn Res"},{"key":"2026092309050934000_52.Suppl_2.s13.12","doi-asserted-by":"crossref","first-page":"3800","DOI":"10.1016\/j.matpr.2021.01.539","article-title":"Ormeloxifene-Hyaluronic acid microfibers for breast cancer therapy","volume":"45","author":"Kumar","year":"2021","journal-title":"Mater Today Proc"},{"key":"2026092309050934000_52.Suppl_2.s13.13","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.canlet.2014.10.009","article-title":"Ormeloxifene efficiently inhibits ovarian cancer growth","volume":"356","author":"Maher","year":"2015","journal-title":"Cancer Lett"},{"key":"2026092309050934000_52.Suppl_2.s13.14","doi-asserted-by":"publisher","DOI":"10.1007\/BF00689679"},{"key":"2026092309050934000_52.Suppl_2.s13.15","doi-asserted-by":"crossref","first-page":"105750","DOI":"10.1016\/j.jddst.2024.105750","article-title":"Folic acid-tripeptide-conjugated synthetic biodegradable nanoparticle-loaded with Ormeloxifene potentially inhibited breast cancer xenograft tumor","volume":"97","author":"Sen","year":"2024","journal-title":"J Drug Deliv Sci Technol"},{"key":"2026092309050934000_52.Suppl_2.s13.16","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1007\/s10495-017-1346-6","article-title":"Centchroman induces redox-dependent apoptosis and cell-cycle arrest in human endometrial cancer cells","volume":"22","author":"Shyam","year":"2017","journal-title":"Apoptosis"},{"key":"2026092309050934000_52.Suppl_2.s13.17","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2026092309050934000_52.Suppl_2.s13.18","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"2026092309050934000_52.Suppl_2.s13.19","doi-asserted-by":"publisher","DOI":"10.1136\/bmjebm-2017-110853"},{"key":"2026092309050934000_52.Suppl_2.s13.20","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"2026092309050934000_52.Suppl_2.s13.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.04.026"},{"key":"2026092309050934000_52.Suppl_2.s13.22","article-title":"Improving the acceptance rate of centchroman as a postpartum contraceptive through a quality improvement initiative","volume":"14","author":"Sarkar","year":"2022","journal-title":"Cureus"},{"key":"2026092309050934000_52.Suppl_2.s13.23","first-page":"134","article-title":"Single dose levonorgestrel and two regimens of centchroman for emergency contraception","volume":"9","author":"Mittal","year":"2008","journal-title":"J Turk Ger Gynecol Assoc"},{"key":"2026092309050934000_52.Suppl_2.s13.24","unstructured":"Nityanand S , Singh L , Srivastava JS , et al . Contraceptive efficacy and safety of centchroman with biweekly-cum-weekly schedule. Central Drug Research Institute; 1994."},{"key":"2026092309050934000_52.Suppl_2.s13.25","unstructured":"Nityanand S , et al . Clinical evaluation of centchroman: a new oral contraceptive. Lucknow, India: Central Drug Research Institute, Lucknow and K.G.Medical College, 1988."},{"key":"2026092309050934000_52.Suppl_2.s13.26","doi-asserted-by":"crossref","first-page":"4204","DOI":"10.18203\/2320-1770.ijrcog20194594","article-title":"A study of Centchroman users with special reference to its contraceptive benefit","volume":"8","author":"Doke","year":"2019","journal-title":"Int J Reprod Contracept Obstet Gynecol"},{"key":"2026092309050934000_52.Suppl_2.s13.27","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.18203\/2320-1770.ijrcog20203322","article-title":"A study to compare acceptability, safety and continuation rates of combined hormonal pill and centchroman as post abortion contraceptives","volume":"9","author":"Miuli","year":"2020","journal-title":"Int J Reprod Contracept Obstet Gynecol"},{"key":"2026092309050934000_52.Suppl_2.s13.28","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.18203\/2320-1770.ijrcog20243590","article-title":"Study of acceptability, efficacy and side effects of non-steroidal contraceptive ormeloxifene and its comparative evaluation with combined oral contraceptives","volume":"13","author":"Gupta","year":"2024","journal-title":"Int J Reprod Contracept Obstet Gynecol"},{"key":"2026092309050934000_52.Suppl_2.s13.29","doi-asserted-by":"crossref","first-page":"203","DOI":"10.18203\/2320-1770.ijrcog20205769","article-title":"Comparison of centchroman and PPIUCD in terms of efficacy, safety and continuation rate in immediate postpartum period","volume":"10","author":"Gupta","year":"2020","journal-title":"Int J Reprod Contracept Obstet Gynecol"},{"key":"2026092309050934000_52.Suppl_2.s13.30","unstructured":"Ganguli G , Mukherjee K , Raman N . Centchroman, a safe contraceptive coverage following medical termination of pregnancy. J Obstet Gynaecol India 1995;649\u201353."},{"key":"2026092309050934000_52.Suppl_2.s13.31","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.18203\/2320-1770.ijrcog20251583","article-title":"Exploring the efficacy of centchroman as a postpartum contraceptive: an observational study","volume":"14","author":"Chhatria","year":"2025","journal-title":"Int J Reprod Contracept Obstet Gynecol"},{"key":"2026092309050934000_52.Suppl_2.s13.32","doi-asserted-by":"publisher","DOI":"10.1016\/0010-7824(95)00214-U"},{"key":"2026092309050934000_52.Suppl_2.s13.33","unstructured":"Puri V , Dhmmn BN . Pharmacology for health in Asia. New Delhi: Allied Publishers, 1988."},{"key":"2026092309050934000_52.Suppl_2.s13.34","doi-asserted-by":"crossref","unstructured":"R A , Pillai S , S S , et al . Effectiveness and safety of ormeloxifene and medroxyprogesterone acetate in dysfunctional uterine bleeding - A prospective interventional quasi-randomized interval clinical study. Natl J Physiol Pharm Pharmacol 2020;1. doi:10.5455\/njppp.2021.11.10285202024102020","DOI":"10.5455\/njppp.2021.11.10285202024102020"},{"key":"2026092309050934000_52.Suppl_2.s13.35","doi-asserted-by":"publisher","DOI":"10.1067\/mob.2002.123938"},{"key":"2026092309050934000_52.Suppl_2.s13.36","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-5122(02)00342-0"},{"key":"2026092309050934000_52.Suppl_2.s13.37","doi-asserted-by":"publisher","DOI":"10.1210\/jc.86.2.755"},{"key":"2026092309050934000_52.Suppl_2.s13.38","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0010-7824(02)00359-1","article-title":"A randomized comparative study on mifepristone alone and in combination with tamoxifen for emergency contraception","volume":"66","author":"Changhai","year":"2002","journal-title":"Contraception"},{"key":"2026092309050934000_52.Suppl_2.s13.39","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b2890","article-title":"Hormonal contraception and risk of venous thromboembolism: national follow-up study","volume":"339","author":"Lidegaard","year":"2009","journal-title":"BMJ"},{"key":"2026092309050934000_52.Suppl_2.s13.40","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1979.03300070040020"},{"key":"2026092309050934000_52.Suppl_2.s13.41","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9378(98)70047-X"},{"key":"2026092309050934000_52.Suppl_2.s13.42","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1111\/1471-0528.17032","article-title":"Contributions of side effects to contraceptive discontinuation and method switch among Kenyan women: a prospective cohort study","volume":"129","author":"Rothschild","year":"2022","journal-title":"BJOG"},{"key":"2026092309050934000_52.Suppl_2.s13.43","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0b013e31821188ad"}],"container-title":["BMJ Sexual &amp; Reproductive Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjsrh-2026-203329","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T16:05:45Z","timestamp":1790179545000},"score":1,"resource":{"primary":{"URL":"https:\/\/jfprhc.bmj.com\/lookup\/doi\/10.1136\/bmjsrh-2026-203329"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":43,"journal-issue":{"issue":"Suppl 2","published-online":{"date-parts":[[2026,9,23]]},"published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1136\/bmjsrh-2026-203329"],"URL":"https:\/\/doi.org\/10.1136\/bmjsrh-2026-203329","relation":{},"ISSN":["2515-1991","2515-2009"],"issn-type":[{"value":"2515-1991","type":"print"},{"value":"2515-2009","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]}}}